Curis, Inc. (CRIS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Curis, Inc. (CRIS) Healthcare & Pipeline Overview

Curis, Inc. is a biotechnology firm specializing in the discovery and development of cancer therapeutics, with a focus on clinical-stage drug candidates like Emavusertib and CI-8993, and strategic collaborations with Roche and Aurigene to advance its oncology pipeline.

What Is the Investment Thesis for CRIS?

Curis, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily driven by the potential success of its clinical-stage drug candidates, particularly Emavusertib, which is currently in Phase 1/2 trials. Positive clinical trial data could serve as a significant catalyst, driving up the company's market capitalization. The company's collaborations with Roche and Aurigene provide validation of its technology and potential revenue streams. However, the company's negative profit margin of -299.7% and small market cap of $4.00M indicate significant financial risks. Investment is contingent on successful clinical trial outcomes and the ability to secure additional funding or partnerships.

Based on FMP financials and quantitative analysis

CRIS Key Highlights

Market Cap of $4.00M reflects its status as a micro-cap biotechnology company.

• Gross Margin of 99.4% indicates strong potential profitability on product sales, assuming successful commercialization.
• Profit Margin of -299.7% highlights significant ongoing losses due to research and development expenses.
• Beta of 3.06 suggests high volatility compared to the broader market.
• Clinical-stage drug candidate Emavusertib is in Phase 1/2 trials, representing a key value driver.

Who Are CRIS's Competitors?

CRIS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRIS's Key Strengths?

Innovative drug candidates in development.

• Strategic collaborations with Roche and Aurigene.
• Experienced management team.
• Proprietary technology platform.

What Are CRIS's Weaknesses?

Limited financial resources.

• Dependence on clinical trial outcomes.
• High cash burn rate.
• Small market capitalization.

What Could Drive CRIS Stock Higher?

CRIS catalyst: Data readout from Phase 1/2 clinical trial of Emavusertib in non-hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes.

• Initiation of clinical trials for new drug candidates.
• Progress in strategic collaborations with Roche and Aurigene.
• Advancements in pre-clinical programs.

What Are the Key Risks for CRIS?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

• Failure of clinical trials for key drug candidates.
• Regulatory delays or rejection of drug approvals.
• Competition from other biotechnology and pharmaceutical companies.
• Dependence on external funding and partnerships.
• High cash burn rate and potential need for additional financing.

What Are the Growth Opportunities for CRIS?

• Emavusertib Clinical Advancement: The successful completion of Phase 1/2 clinical trials for Emavusertib in non-hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes represents a significant growth opportunity. Positive data could lead to further clinical development, potential regulatory approval, and commercialization. The market for these indications is substantial, with a projected value exceeding $20 billion by 2030. This growth is contingent on demonstrating superior efficacy and safety compared to existing treatments.
• CI-8993 Development: Advancing the development of CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, offers another growth avenue. Successful preclinical and clinical studies could position CI-8993 as a novel immunotherapy for various cancers. The immunotherapy market is experiencing rapid growth, with a projected value of $100 billion by 2028. Curis needs to demonstrate a clear advantage over existing immunotherapies to capture market share.
• Fimepinostat Expansion: Exploring the potential of Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes, for the treatment of patients with MYC-altered diffuse large B-cell lymphoma, presents a targeted growth opportunity. This approach focuses on a specific subset of lymphoma patients, potentially leading to a more personalized and effective treatment. The market for targeted cancer therapies is expanding, with a projected value of $80 billion by 2027. Curis must demonstrate the efficacy of Fimepinostat in this specific patient population.
• Collaboration Expansion: Expanding collaborations with pharmaceutical companies like Roche and Aurigene can provide additional funding, resources, and expertise. These partnerships can accelerate the development and commercialization of Curis's drug candidates. The pharmaceutical industry is increasingly relying on collaborations to drive innovation, with deal values reaching record levels in recent years. Curis needs to actively seek and cultivate strategic partnerships to maximize its growth potential.
• Pipeline Expansion: Expanding the pipeline with new drug candidates and therapeutic targets represents a long-term growth opportunity. This can involve internal research and development efforts, as well as in-licensing or acquiring promising technologies. The biotechnology industry is constantly evolving, with new targets and technologies emerging regularly. Curis needs to maintain a strong focus on innovation to remain competitive and drive future growth.

What Threats Does CRIS Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Patent expirations.

What Are CRIS's Competitive Advantages?

• Proprietary drug candidates and intellectual property.
• Strategic collaborations with established pharmaceutical companies.
• Expertise in cancer drug discovery and development.
• Clinical-stage assets with potential for regulatory approval.

What Does CRIS Do?

Curis, Inc., founded in 2000 and headquartered in Lexington, Massachusetts, is a biotechnology company dedicated to the discovery and development of innovative drug candidates for the treatment of various human cancers. The company's focus is on advancing its pipeline of clinical-stage and pre-clinical programs targeting hematologic malignancies and solid tumors. Curis's lead clinical-stage drug candidate is Emavusertib, an oral small molecule currently in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Another key asset is CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. Curis has established strategic collaborations with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma. Additionally, the company collaborates with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. These partnerships are crucial for funding research and expanding the reach of their therapies.

What Products and Services Does CRIS Offer?

• Discovers and develops drug candidates for cancer treatment.
• Focuses on hematologic malignancies and solid tumors.
• Develops oral small molecule drugs and monoclonal antibodies.
• Conducts Phase 1/2 clinical trials for lead drug candidates.
• Collaborates with pharmaceutical companies for development and commercialization.
• Advances pre-clinical programs towards clinical development.

How Does CRIS Make Money?

• Develops and patents novel drug candidates.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties from partnered programs.
• Seeks to commercialize proprietary drug candidates independently or through partnerships.

What Industry Does CRIS Operate In?

Curis, Inc. operates within the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The industry is driven by the increasing prevalence of cancer and the demand for innovative therapies. Curis focuses on developing treatments for hematologic malignancies and solid tumors, competing with both large pharmaceutical companies and smaller biotech firms. The success of companies like Curis depends on their ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy.

Who Are CRIS's Key Customers?

• Pharmaceutical companies (through collaborations and licensing agreements).
• Patients with cancer (end-users of approved therapies).
• Healthcare providers (prescribers of approved therapies).
• Research institutions (collaborators in drug discovery and development).

Over the past six months, Curis, Inc. insiders filed 30 SEC Form 4 transactions — 5 sales and 25 purchases. On net that is roughly 1.2M shares acquired (about $1.7M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Curis, Inc.

Revenue for Curis, Inc. came in at $1.1M during Q4 2025, a 64.2% contraction versus the preceding quarter. The company recorded net income of $19.4M, with diluted EPS of $24.60.

CRIS Valuation & Market Position

With a $4.00M market cap, Curis, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CRIS's quantitative score of 17/100 is below the peer average of 78/100.

Key Financial Metrics

Return on assets is -71.3%, showing how much profit it generates from its asset base. A current ratio of 1.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.4%, the inverse of the P/E and a quick read on earnings relative to price.

Curis, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Curis, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 27.3% above estimates on average.

Wall Street analysts project Curis, Inc. revenue of about $1.8M for fiscal 2026, with EPS near $-40.18.

Company Profile

Curis, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Lexington, US. The company is led by CEO James Dentzer. CRIS has traded publicly since 2000.

CRIS Financials

CRIS Latest News

CRIS Analyst Consensus

CRIS MoonshotScore

Curis, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources